



Correction

Correction: Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial

The PLOS ONE Staff

There is an error in the Materials and Methods section. In the first sentence of the subheading “Design and Intervention”, the ATV dosage is incorrect. The correct ATV dosage is 400 mg. Please note that the dosage is correct in the Supporting Information protocol.

Reference

1. Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, et al. (2014) Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial. PLoS ONE 9(5): e96187. doi:10.1371/journal.pone.0096187

Citation: The PLOS ONE Staff (2014) Correction: Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial. PLoS ONE 9(7): e103925. doi:10.1371/journal.pone.0103925

Published: July 23, 2014

Copyright: © 2014 The PLOS ONE Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.